戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rosis, Paget's disease, bone metastasis, and hypercalcemia of malignancy.
2 (PTHrP) is the agent responsible for humoral hypercalcemia of malignancy.
3  immune deficiency mice and produced humoral hypercalcemia of malignancy.
4 as the tumor product responsible for humoral hypercalcemia of malignancy.
5 vered as a tumor product that causes humoral hypercalcemia of malignancy.
6 , the drug was approved for the treatment of hypercalcemia of malignancy.
7 tivity in a syngeneic tumor model of humoral hypercalcemia of malignancy.
8 phonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases.
9 g as a novel therapeutic approach in humoral hypercalcemia of malignancy and possibly multiple myelom
10                                      Humoral hypercalcemia of malignancy (HHM) is caused by the secre
11 se associated with breast cancer and humoral hypercalcemia of malignancy (HHM) that occurs with or wi
12 imately 80% of ATLL patients develop humoral hypercalcemia of malignancy (HHM), a life-threatening co
13 ized as the major causative agent of humoral hypercalcemia of malignancy (HHM).
14 us type-1 (HTLV-1) infection develop humoral hypercalcemia of malignancy (HHM).
15                        In a model of humoral hypercalcemia of malignancy in which PTHrP secreted by s
16                                              Hypercalcemia of malignancy is associated with poor surv
17                                              Hypercalcemia of malignancy is not uncommon in patients
18    The potent effects of OPG in this humoral hypercalcemia of malignancy model suggest a potential th
19                                      Humoral hypercalcemia of malignancy results from the effects of